Developing a Novel Costimulatory Antigen Receptor With Dual CD28/ CD40 Signaling Domains to Improve Adoptive Cell Therapies

Time: 11:30 am
day: Day One


• Utilizing a novel platform to overcome poor endogenous costimulation and leverage the diverse TCR repertoire of TILs while amplifying antitumor activity

• Improving primary human ovarian TIL function

• Optimizing TIL therapies to improve scalability, logistics and accessibility